Sign in

    Alley Bratzel

    Vice President and Senior Research Analyst at Piper Sandler

    Allison Bratzel is a Vice President and Senior Research Analyst at Piper Sandler, specializing in biotechnology sector equity research with a focus on companies including AbCellera Biologics, Abivax, Akebia Therapeutics, ALX Oncology, argenx, Biohaven, BioMarin, Codexis, Cogent Biosciences, enGene, Humacyte, Immuneering, Incyte, Ionis Pharmaceuticals, Replimune, Rigel Pharmaceuticals, Roivant Sciences, Scholar Rock, Travere Therapeutics, Tyra Biosciences, and Ultragenyx. She maintains a strong performance record with a 66% success rate and a 54.1% average return over the past year according to TipRanks data. Bratzel began her career as an associate in biotechnology research at Raymond James and Robert W. Baird before joining Piper Sandler in 2017. She holds the Chartered Financial Analyst (CFA) designation and has academic credentials in finance and economics from Michigan State University.

    Alley Bratzel's questions to Biohaven (BHVN) leadership

    Alley Bratzel's questions to Biohaven (BHVN) leadership • Q3 2021

    Question

    Alley Bratzel, on behalf of Chris Raymond at Piper Sandler, inquired about the composition of the $740 million in potential milestones from the Pfizer deal, specifically the split between regulatory and commercial achievements. She also asked how NURTEC ODT's profile is resonating with physicians compared to a newly approved competitor.

    Answer

    CEO Dr. Vlad Coric stated that specific details on the milestone split would be available in filings but emphasized the deal's role in accelerating ex-U.S. revenue. He reiterated that NURTEC ODT's unique profile as the only single therapy for both acute treatment and prevention remains a key differentiator and the primary driver of its market share leadership against competitors.

    Ask Fintool Equity Research AI